Feb. 20, 2019

Page 1

Feb. 20, 2019

|

Volume XCIX

|

Est. 1929

|

www.sjuhawknews.com

|

The Student Newspaper of Saint Joseph’s University

Emily Fordham ’21 stands in her room and displays her Continuous Glucose Monitoring System and insulin pump system. PHOTOS: MITCHELL SHIELDS ’22/THE HAWK

Students with diabetes worry about affording insulin ERIN BREEN ’19 News Editor When Emily Fordham ’21, a psychology major, was diagnosed with type 1 diabetes last summer, she started wondering if she had chosen the right career path, one that would pay her medical bills. “It isn’t the most lucrative industry,” Fordham said. “Once I wrapped my head around what I was living with, I started asking questions like, ‘How much does this cost?’” When it comes to insulin, the answer to that question can be staggering. The price of insulin has increased over 500 percent since 2005, according to a study done by the

Health Care Cost Institute. In 2017, American diabetes patients paid $237 billion in direct medical costs, an average of $16,750 per patient, according to WebMD Health News. The development of type 1 diabetes occurs when the pancreas fails to produce the insulin a person needs, making the individual dependent on injected insulin for the body to function properly. Type 2 diabetes is the body’s resistance to naturally produced insulin. In this case, changes to diet and lifestyle are often recommended before insulin treatment. For people with diabetes, the growing cost of insulin in the last decade has led people to turn to the black market, travel abroad

to buy insulin, or buy what they can afford and ration. George Sillup, Ph.D., chair and associate professor of pharmaceutical and healthcare marketing, said insulin costs are the result of aggressive price increases by manufacturers. “Manufacturers have adjusted their formulations to create new analogs that can extend their product’s patent protection,” Sillup said. “This extended patent protection, or ‘evergreening,’ enables the company to prevent a less expensive or generic (biosimilar) version of their products so they can continue to raise their prices without other competition.” Sillup also blamed a lack of competition in the market. The top three manufacturers

of insulin, Sanofi, Novo Nordisk and Eli Lilly and Company, continue to raise their prices, leaving those affected only one choice - to keep paying, Sillup said. For many college students, these costs are an added worry to decisions regarding their futures. “Everyone in college is worried about what they’re going to do after college, how are they going to support their dreams,” Fordham said. “Then having this additional cost on top of that, it definitely factors into how you’re going to do things.” SEE PG. 3

Fordham uses a Personal Diabetes Managment system, on the left, to regulate her insulin levels, after switching over the winter break from using needles.

OPINIONS

FIND US ON SOCIAL MEDIA

@SJUHAWKNEWS

07

Learning how to deal with feelings of selfdoubt

LIFESTYLE

10

Theatre department performs “Beauty and the Beast”

SPORTS

14

Phil “Pops” Martelli leaves powerful legacy


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.